CollPlant Biotechnologies Launches Redesigned Corporate Website
Rhea-AI Summary
CollPlant (Nasdaq: CLGN) launched a redesigned corporate website on March 18, 2026 to centralize investor, partner, and stakeholder information. The site expands details on the company's rhCollagen technology, product pipeline (breast implants, dermal fillers, bioinks), collaborations, SEC filings, and governance.
The update aims to improve transparency, accessibility, and engagement as CollPlant advances its clinical and preclinical programs and commercialization objectives.
Positive
- None.
Negative
- None.
News Market Reaction – CLGN
On the day this news was published, CLGN gained 1.67%, reflecting a mild positive market reaction. This price movement added approximately $134K to the company's valuation, bringing the market cap to $8M at that time.
Data tracked by StockTitan Argus on the day of publication.
REHOVOT,
The new website provides expanded information regarding the Company's technology platform, product pipeline, strategic collaborations and corporate governance, and is intended to enhance transparency and accessibility for investors, partners, and other stakeholders.
The redesigned site includes updated sections detailing:
- CollPlant's proprietary rhCollagen technology and manufacturing platform
- The Company's product development pipeline, including regenerative breast implants, dermal fillers, and bioinks
- Strategic partnerships and collaboration initiatives
- Investor relations resources, including SEC filings, financial reports, and corporate presentations
- Corporate governance materials and leadership information
Yehiel Tal, Chief Executive Officer of CollPlant, stated: "We are pleased to introduce our redesigned corporate website, which reflects CollPlant's continued advancement as a regenerative medicine and aesthetics company. The new platform provides clear and comprehensive information regarding our rhCollagen technology, product pipeline, and strategic direction. We believe the enhanced website will improve engagement with business partners and investors as we continue to execute on our development and commercialization objectives."
The website is intended to serve as a central source of information regarding CollPlant's scientific platform, clinical and preclinical programs, and corporate updates.
For more information, visit www.CollPlant.com or contact CollPlant at info@CollPlant.com.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, including its objectives to provide clear and comprehensive information regarding the rhCollagen technology, product pipeline, and strategic direction and strategy to improve engagement with business partners and investors, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
Logo - https://mma.prnewswire.com/media/2217353/5870835/CollPlant_Logo.jpg
Photo - https://mma.prnewswire.com/media/2936916/New_Website.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-launches-redesigned-corporate-website-302717384.html
SOURCE CollPlant
FAQ
What did CollPlant (CLGN) announce on March 18, 2026 about its website?
Where can investors find CollPlant (CLGN) SEC filings and financial reports after the March 18, 2026 update?
Does the new CollPlant (CLGN) website include product pipeline details and which programs are listed?
How does CollPlant (CLGN) say the website change will affect engagement with partners and investors?
Does CollPlant (CLGN) still reference its earlier 2021 collaboration with Allergan on the new website?
